---
title: "MAIA Biotechnology activates first U.S. site for THIO-101 Phase 2 expansion, NIH funds $2.3M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283011482.md"
description: "MAIA Biotechnology has activated its first U.S. site for the Phase 2 expansion trial of THIO-101, targeting heavily pre-treated third-line NSCLC patients resistant to chemotherapy. The Summit Medical Group in New Jersey will facilitate U.S. patient access. The expansion is supported by a $2.3 million NIH grant, with plans to test ateganosine in combination with cemiplimab and as monotherapy at additional sites in 2026. MAIA's lead drug has FDA Fast Track designation, with previous data showing overall survival beyond 24 months in certain patients."
datetime: "2026-04-16T13:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283011482.md)
  - [en](https://longbridge.com/en/news/283011482.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283011482.md)
---

# MAIA Biotechnology activates first U.S. site for THIO-101 Phase 2 expansion, NIH funds $2.3M

**MAIA Biotechnology activated the first U.S. site for its Phase 2 THIO-101 expansion trial in third-line NSCLC and has $2.3M NIH funding for U.S. evaluation.**

**Key Highlights:**

-   Activated Summit Medical Group in New Jersey as first U.S. site for THIO-101 Phase 2 expansion, opening U.S. patient access.
-   Expansion targets heavily pre-treated 3L NSCLC patients resistant to chemotherapy and checkpoint inhibitors, expanding eligible pool.
-   Study tests ateganosine sequenced with cemiplimab and ateganosine monotherapy across additional planned U.S. sites in 2026.
-   U.S. expansion is funded by a $2.3 million NIH grant to support third-line treatment evaluation.
-   MAIA holds FDA Fast Track designation for its lead drug; prior data show OS beyond 24 months in eight patients when sequenced with a CPI.

Original SEC Filing: MAIA Biotechnology, Inc. \[ MAIA \] - 8-K - Apr. 16, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [MAIA.US](https://longbridge.com/en/quote/MAIA.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [MAIA Biotechnology to Terminate ATM Agreement With H.C. Wainwright After Raising $5.68M](https://longbridge.com/en/news/286468852.md)
- [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock News](https://longbridge.com/en/news/286772955.md)
- [Vertex Says Health Canada Accepts Suzetrigine Application for Review](https://longbridge.com/en/news/287257602.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)